Senior Director, Biostatistics

Braveheart Bio•San Francisco, CA
•$280,000 - $320,000

About The Position

Braveheart Bio is a clinical-stage biopharmaceutical company developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor being developed for obstructive and non-obstructive HCM. The Senior Director, Biostatistics, is a hands-on program-level statistical leader for BHB-1893, reporting to the VP, Head of Biometrics. The role owns the statistical strategy, design, analysis, and interpretation of late-stage Phase 2 and Phase 3 studies while directly performing substantial statistical work. It manages CRO and vendor biostatistics and programming work, collaborates with external partners, represents biostatistics on program teams and in health authority interactions, and leads statistical contributions to regulatory filings. The role partners with Clinical Development, Clinical Operations, Data Management, Regulatory, Safety, Medical Affairs, and Clinical Pharmacology. It also contributes to the processes and standards of a growing late-stage organization. The ideal candidate has deep late-stage and regulatory expertise, sound scientific judgment, and a preference for hands-on work in a lean, fast-moving biotech environment.

Requirements

  • MS or PhD in Biostatistics, Statistics, or a closely related quantitative field.
  • At least 12 years of biostatistics experience with a PhD, or at least 15 years with an MS, in the biotechnology, pharmaceutical, or CRO industry.
  • Direct experience as lead statistician on late-stage Phase 2 and Phase 3 programs, including dose-ranging and pivotal trials, from design through database lock, analysis, and reporting.
  • Hands-on regulatory filing experience, having led or served as a senior statistician on at least one NDA, BLA, or MAA submission, including ISS/ISE, CDISC submission datasets, and responses to health authority questions.
  • Deep expertise in clinical trial design, estimands, multiplicity, missing data methods, interim analyses, and group sequential and adaptive designs.
  • Proven experience managing CROs and statistical vendors and driving accountability, quality, and on-time delivery.
  • Experience collaborating effectively with external partners, such as co-development or licensing partners, academic groups, and independent DMCs.
  • Strong hands-on statistical skills, including the ability to independently perform analyses and simulations and review programming outputs; people management experience is not required.
  • Working knowledge of SAS and/or R, CDISC standards (SDTM, ADaM), GCP, ICH E9/E9(R1), and relevant FDA and EMA guidance.
  • Ability to communicate complex statistical concepts clearly to non-statisticians, including executives, the Board, investigators, and regulators.
  • Demonstrated ability to work cross-functionally in a lean, fast-paced development environment.
  • Strong written and verbal communication skills and a collaborative, team-oriented approach.
  • Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
  • Flexible, proactive, hands-on mindset with a roll-up-your-sleeves, can-do attitude.

Nice To Haves

  • Experience in cardiovascular clinical development, ideally including HCM or heart failure, and familiarity with endpoints such as peak VO2, KCCQ, NYHA class, and echocardiographic measures such as LVOT gradient.
  • Experience supporting multiple regulatory filings and taking a product through approval and launch.
  • Prior experience as program statistical lead in a small or mid-sized biotech transitioning into late-stage development.
  • Experience preparing for or presenting at FDA Advisory Committee meetings.
  • Experience with independent DMC/DSMB interactions and statistical reporting.

Responsibilities

  • Serve as program statistical lead for BHB-1893, setting and executing the statistical strategy for Phase 2 and Phase 3 development across obstructive and non-obstructive HCM, aligned with the VP, Head of Biometrics.
  • Provide statistical leadership on study design, including endpoint selection, sample size and power, randomization, estimands, multiplicity control, and adaptive or innovative designs where appropriate.
  • Personally author statistical sections of protocols, statistical analysis plans, DMC charters, randomization specifications, and TFL shells.
  • Manage CRO and external biostatistics and statistical programming vendors, including selection, scopes of work, budgets, change orders, timelines, and deliverable quality; hold vendors accountable and escalate issues as needed.
  • Collaborate with external partners, including co-development or licensing partners, academic collaborators, steering committees, independent DMC statisticians, and key opinion leaders, to align on statistical strategy, analyses, and data sharing.
  • Serve as statistical lead in FDA, EMA, and other health authority interactions, including End-of-Phase 2, Type B/C, and Scientific Advice meetings, and responses to agency questions.
  • Lead statistical contributions to NDA/MAA submissions, including integrated summaries of safety and efficacy, clinical study reports, and Module 2 summaries.
  • Partner with Data Management and Statistical Programming on interim analyses, DMC data cuts, unblinding procedures and firewalls, database locks, and delivery of CDISC-compliant SDTM and ADaM datasets.
  • Interpret and communicate study results to executive leadership, the Board, investigators, and external partners; support topline readouts, publications, and scientific presentations.
  • Collaborate with Clinical Pharmacology and Translational Science on exposure–response, PK/PD, biomarker, and model-informed drug development analyses.
  • Support medical affairs, real-world evidence, and health economics analyses, including exploratory and post-hoc analyses.
  • Perform hands-on simulations, sample size and power calculations, and probability-of-success analyses to support study design and program decisions.
  • Contribute to biostatistics SOPs, work instructions, templates, and standards, supporting inspection readiness and compliance with GCP, ICH E9, and regulatory requirements.
  • Perform independent statistical analyses and quality reviews of CRO outputs using SAS and/or R.

Benefits

  • Competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service